All entries for: Exelixis Inc.

February 10, 2026

Exelixis Inc.

Negative Outlook

Alameda, CA
1,001-5,000 employees

Over time, the IRA could reduce the revenues we are able to collect from sales of our products or present challenges for payor negotiations and formulary access for our products, as well as increase our government discount and rebate liabilities. However, it is unclear how the IRA will be effectuated or changed under the current U.S. administration as well as the degree of impact that the IRA will ultimately have upon our business.

Disease Area: Oncology
Drug Type: Small Molecule
November 4, 2025

Exelixis Inc.

Neutral Outlook

Alameda, CA
1,001-5,000 employees

The administration has directed agencies to pursue MFN pricing through new models and potential regulatory actions, but the scope, timing, and impact of these initiatives remain uncertain.

Scroll to Top